Mondelez (MDLZ) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Mondelez (MDLZ) reported Q2 2025 revenue of $8.98 billion, a 7.7% year-over-year increase that surpassed analyst estimates by 1.18%. While diluted EPS of $0.73 beat consensus by 7.35%, it represented a decline from $0.86 in the prior year. Geographic performance was mixed, with strong growth in Europe (+18.7%) and AMEA (+14.7%) offsetting revenue declines in North America (-3.5%) and Latin America (-3.1%). The stock's recent 3.2% gain trailed the S&P 500, and it holds a Zacks Rank #3 (Hold).

Analysis

Mondelez (MDLZ) presented a mixed financial picture for its second quarter of 2025, characterized by a top-line beat offset by deteriorating profitability and regional weakness. The company reported a 7.7% year-over-year revenue increase to $8.98 billion, surpassing consensus estimates by 1.18%. However, this growth was overshadowed by a significant decline in earnings per share to $0.73 from $0.86 in the prior year, even though the result beat analyst expectations by 7.35%. The headline revenue strength was driven entirely by robust performance in international markets, with Europe growing 18.7% and AMEA by 14.7% year-over-year, both exceeding forecasts. This was contrasted sharply by revenue contractions in North America (-3.5%) and Latin America (-3.1%), with the North American result also missing analyst targets. The stock's recent price appreciation of 3.2% has slightly lagged the S&P 500 composite, reflecting investor apprehension and aligning with its Zacks Rank #3 (Hold) status, which suggests the market is pricing in these underlying challenges.

Key Decisions for Investors

• Investors should weigh the positive revenue surprise driven by strong European (+18.7%) and AMEA (+14.7%) growth against the significant year-over-year EPS decline and concerning revenue contraction in the key North American market (-3.5%).
• Monitor future earnings reports for a stabilization or reversal of the negative revenue trends in the Americas, as continued weakness could threaten the company's overall growth trajectory despite international strength.
• Given the conflicting signals of a top-line beat but declining profitability and the stock's recent market underperformance, maintaining a neutral stance may be prudent until there is clearer evidence of margin improvement and a return to growth in all geographic segments.